Alnylam Pharmaceuticals, Inc (ALNY) shares are up almost 8% pre-market after the company reported positive results from a trial of its ALN-HBV for the treatment of hepatitis B virus in chimpanzees.
“Alnylam’s new ALN-HBV program is a mature, pre-clinical asset acquired through the company’s acquisition of Sirna from Merck. We are very encouraged by the data we are presenting for the first time today, which we believe constitute the most robust proof-of-concept pre-clinical data to date with an RNAi therapeutic for the treatment of HBV,” said company vice president Laura Sepp-Lorenzino.
The stock recently traded at $58.50 and has moved in a 52-week range of $25.57 – $112.57.
Latest posts by Anne-Marie Jackson (see all)
- Antarctica Might Be Home To Around 100 Volcanoes - Aug 16, 2017
- Walmart Issues An Apology For Back-To-School And Guns Mishap - Aug 11, 2017
- Extremely Rare Primate Skull Might Offer New Look At Our Ancestry - Aug 10, 2017